Quick orientationEvidence update: 6 October 2026
What is Retatrutide?
Retatrutide is Lilly's once-weekly triple hormone-receptor agonist targeting GIP, GLP-1 and glucagon receptors. It began attracting attention after unusually large Phase 2 weight-loss results; by 2026, pivotal Phase 3 data had strengthened the evidence considerably, although retatrutide remains investigational rather than a generally approved medicine.
Why people are interested
The potential benefits, unpacked.
Here are the goals and claims that bring readers to this guide. The evidence note shows which part is demonstrated, early research or still a question.
Very large weight loss
The central reason for the attention. Phase 2 produced mean losses up to 24.2% at 48 weeks, while Phase 3 TRIUMPH-1 reported substantially larger losses over 80 weeks at the highest dose.
Three metabolic signals in one molecule
Retatrutide activates GIP, GLP-1 and glucagon receptors. Researchers are testing whether adding glucagon-receptor activity to incretin signalling can improve energy balance and weight loss.
Metabolic complications of obesity
The programme extends beyond the bathroom scales, with research covering glycaemia and obesity-related complications; those outcomes need to be read study by study rather than assumed from weight loss alone.
What is it actually doing?
GLP-1 receptor agonism contributes to appetite and satiety signalling and glucose-dependent insulin effects. GIP receptor agonism adds another nutrient-responsive incretin pathway. Retatrutide also activates the glucagon receptor, a pathway linked to hepatic fuel handling and energy expenditure.
The interesting question is not simply whether all three receptors are activated — they are — but whether the balance of activity produces a better clinical result than one- or two-receptor medicines while keeping adverse effects acceptable. The Phase 2 and Phase 3 programmes are designed to answer that in people.
Results at a glanceHuman evidence
What did the studies actually find?
mean weight reduction at 48 weeks in the Phase 2 12 mg group
338 adults were randomised; placebo averaged 2.1% loss. Weight-loss curves had not clearly plateaued by week 48.
average loss at 80 weeks with 12 mg in TRIUMPH-1
Lilly reported 70.3 lb average loss and 45.3% of participants achieving at least 30% weight loss; the Phase 3 paper was published in NEJM in September 2026.
maintenance doses studied in Phase 3 TRIUMPH-1
These are trial arms reached through protocolised escalation, not a menu of self-selected doses.
Study evidenceStudy deep dives
The important studies, translated into normal English.
Each synopsis keeps the trial design, actual results and limitations together. Graphs below are redrawn from the cited numerical results so you can see the size of the effect without having to decode a journal figure.
TRIUMPH-1 Phase 3 — NEJM 2026
Phase 3, randomised, double-blind, placebo-controlled · 2,339 adults with obesity without diabetes · 80 weeksThis is now the pivotal obesity study. Participants received once-weekly retatrutide 4 mg, 9 mg or 12 mg, or placebo. In the peer-reviewed treatment-regimen analysis, average weight change was −17.6%, −23.7% and −25.0% versus −3.9% with placebo. Lilly's efficacy-estimand analysis — which asks a different statistical question about efficacy under treatment — reported −19.0%, −25.9% and −28.3% versus −2.2%. The page shows both rather than mixing them.
The headline is not merely that retatrutide beat placebo: weight loss increased with dose and reached roughly a quarter of starting body weight on average in the peer-reviewed primary analysis at the two higher doses.
| Group | ≥25% loss | ≥30% loss | ≥35% loss |
|---|---|---|---|
| Placebo | 2.2% | 0.5% | 0.3% |
| 4 mg | 27.8% | 15.3% | 5.9% |
| 9 mg | 52.9% | 37.9% | 20.8% |
| 12 mg | 62.5% | 45.3% | 27.2% |
What it doesn't prove: Different estimands produce different headline percentages. Results are population averages from a monitored trial and do not establish an individual's ideal dose or the safety of non-trial products.
Read the original study / source ↗Phase 2 obesity trial — NEJM 2023
Phase 2, double-blind, randomised, placebo-controlled · 338 adults · 48 weeksThis was the study that first made retatrutide difficult to ignore. Once-weekly groups targeted 1, 4, 8 or 12 mg. At 48 weeks average weight change was −8.7%, −17.1%, −22.8% and −24.2%, compared with −2.1% for placebo. The curves were still heading down at week 48 in the higher-dose groups.
There was a clear dose-response signal, and 12 mg averaged 24.2% weight loss by week 48. The study also showed why titration matters: gastrointestinal side effects were dose-related and were partly reduced by starting at 2 mg rather than 4 mg.
| Group | ≥5% loss | ≥10% loss | ≥15% loss |
|---|---|---|---|
| Placebo | 27% | 9% | 2% |
| 4 mg | 92% | 75% | 60% |
| 8 mg | 100% | 91% | 75% |
| 12 mg | 100% | 93% | 83% |
What it doesn't prove: Phase 2 was relatively small and US-only. It was designed to explore dose, efficacy and safety, not to settle long-term outcomes.
Read the original study / source ↗
Dosing referenceResearch, licensed & reported protocols
What doses and schedules are actually documented?
Human research or licensed product information is separated from clinic and community practice. These are source-attributed reference protocols, not personalised dosing recommendations.
Human research / licensed or product dosing
| Protocol / context | Amount & frequency | Duration | Titration | Evidence |
|---|---|---|---|---|
| Phase 2 — 1 mg | 1 mg SC once weekly | 48 weeks | Fixed | Human Phase 2 |
| Phase 2 — 4 mg target | Start 2 or 4 mg; target 4 mg | 48 weeks | Escalation every 4 weeks where needed | Human Phase 2 |
| Phase 2 — 8 mg target | Start 2 or 4 mg; target 8 mg | 48 weeks | Gradual 4-week escalation up to 12 weeks | Human Phase 2 |
| Phase 2 — 12 mg target | Start 2 mg; target 12 mg | 48 weeks | Gradual 4-week escalation up to 12 weeks | Human Phase 2 |
| TRIUMPH-1 Phase 3 | 4 mg, 9 mg or 12 mg SC once weekly target arms | 80 weeks | Protocol-defined escalation | Human Phase 3, published Sep 2026 |
Community / clinic / specialist protocols
| Pattern | Amount & frequency | Cycle | Progression | Status |
|---|---|---|---|---|
| Low community start | ~0.5–1 mg weekly | Often ≥4 weeks | Slow escalation | Community; below trial starting doses |
| Trial-adjacent start | ~2 mg weekly | ~4 weeks before increase | 4-week steps often imitated | Community |
| Common later range | ~4–8 mg weekly | Long-term | Individual slower/faster escalation reported | Community |
| Higher community / trial-adjacent | 9–12 mg weekly | Long-term | Usually reached after multiple steps | Community; higher exposure |
Retatrutide remains investigational despite Phase-3 publication. Phase 2 showed GI events concentrated during escalation and partly mitigated by the lower 2 mg starting dose.
Evidence checked: 7 October 2026
Routes and formulations matter. A topical study does not validate injection; an IV research dose does not establish a fixed SC dose; and evidence for one molecular form must not be silently transferred to another.
Community reportsCommunity reports
What are people actually doing?
People often deviate from the trial titration
Reddit reports include lower starts, split doses and shorter intervals. The variation is useful for understanding what people are doing, but it also means anecdotes cannot be compared cleanly with the clinical trials.
View the discussion on Reddit ↗Some report effects wearing off before day seven
Community posts describe appetite returning late in the week and users experimenting with shorter intervals or split schedules. That is anecdotal practice, not evidence that a shorter interval is safer or more effective.
View the discussion on Reddit ↗Side-effect sensitivity varies considerably
Posts range from mild nausea and fatigue to substantial gastrointestinal intolerance. Trial evidence is more reliable for estimating adverse-event frequency; community reports are useful for illustrating variability.
View the discussion on Reddit ↗
Safety and uncertaintySafety, side effects & what we don't know
In Phase 2, the most common adverse events were gastrointestinal, generally mild to moderate and dose-related. Lower starting doses partly mitigated those effects.
Heart rate increased in a dose-dependent fashion in Phase 2, peaking around week 24 and then declining. That is a useful reminder that the glucagon component makes retatrutide more than simply 'another GLP-1'.
Retatrutide is investigational. Products sold outside clinical trials are not equivalent to Lilly's trial product, and purity, concentration, sterility and identity add separate uncertainties.
QuestionsQuestions worth asking
Is retatrutide approved yet?
As of this guide's 6 October 2026 update, retatrutide is still described as investigational. Strong Phase 3 results are not the same thing as regulatory approval.
Is 12 mg the 'best' dose?
No such conclusion follows from the headline number. Higher doses produced greater average weight loss in trials but dosing also affects tolerability. Trial arms answer population-level research questions, not an individual's ideal dose.
Why do Reddit schedules look different from the studies?
People self-experiment with lower starts, split dosing, shorter intervals and combinations. Those reports are worth documenting as community behaviour, but they have not been validated against the trial schedule.
Primary sourcesStudies, sources & further reading
External links are provided for transparency and further reading. Linking to a study, discussion or organisation does not mean Peptides Peptalk endorses every conclusion on that page.